In a significant breakthrough for early cancer detection and prevention, China has successfully developed its first "tumor gene chip diagnostic kit" in Lanzhou, achieving an accuracy rate of over 95%. According to the Lanzhou Science and Technology Bureau, this innovative "oncology gene chip diagnostic kit," created by Professor Liu Jianyun from the Lanzhou Biochemical Engineering Technology Center, has received certification from the German National Genetic Laboratory and is now being used in preclinical diagnostic applications.
The tumor gene chip technology represents one of the most advanced diagnostic methods available today. This kit employs cutting-edge liquid chip technology to accurately measure the concentration of trace biomarkers in the blood, offering crucial insights for early cancer detection and risk assessment. Leveraging state-of-the-art SNP genotyping instruments and the Illumina platform, the system analyzes genetic data to generate personalized health reports, identifying potential tumor genes and their impact on overall health. This approach empowers individuals to better understand their disease risks, take proactive steps to manage risk factors, and adopt a new model of health management that includes genetic testing, risk assessment, and targeted disease prevention.
Professor Liu explained that genes are functional units of DNA that carry hereditary information, determining life and death. These genetic blueprints are inherited from parents at the moment of conception. The tumor gene test involves taking just 5 ml of peripheral blood from the subject. After extracting and amplifying the genetic material, the gene chip is used to detect key genetic markers, revealing hidden "gene mines" that may lead to disease even before symptoms appear.
Following nearly three years of research and development, the "Tumor Gene Chip Diagnostic Kit" has reached a mature stage and is now being used in clinical settings. Since 2006, it has been tested in over 300 clinical trials across several prestigious institutions, including the Civil Aviation Medical Research Center of the China Civil Aviation Administration, Peking University Affiliated Hospital, Hannover Medical University, and Regensburg University Hospital in Germany. The results showed a specificity of over 80%, with a diagnostic accuracy of more than 95% in 200 patients in Germany. In China, over 100 tests were conducted, showing an accuracy rate of over 98% in screening for potential tumor genes in healthy individuals.
The technology has gained recognition from both domestic and international experts. To bring this high-tech product to market, the Lanzhou Biochemical Engineering Technology Center has partnered with Lanzhou Huazhi Laiwei Medical Equipment Co., Ltd. to industrialize the "Tumor Gene Chip Diagnostic Kit" in Lanzhou.
— Shanghai Medical Device Industry Association
Monosodium Glutamate 98%(MSG)
Fructose Syrup,Glucose Fructose Syrup Gluten,Best High Fructose Corn Syrups,High Fructose Corn Syrup 42
JILIN COFCO BIO-CHEM AND BIO-ENERGY MARKETING CO., LTD , https://www.cofco-biotech.com